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Pancreatic beta-cell regeneration, for example, by inducing proliferation, remains an important goal in developing eﬀective
treatments for diabetes. However, beta cells have mainly been considered quiescent. This “static” view has recently been
challenged by observations of relevant physiological conditions in which metabolic stress is compensated by an increase in beta-
cell mass. Understanding the molecular mechanisms underlining these process could open the possibility of developing novel
small molecules to increase beta-cell mass. Several cellular cell-cycle and signaling proteins provide attractive targets for high
throughput screening, and recent advances in cell culture have enabled phenotypic screening for small molecule-induced beta-
cell proliferation. We present here an overview of the current trends involving small-molecule approaches to induce beta-cell
regeneration by proliferation.
1. Introduction
Both type 1 (T1D) and 2 (T2D) diabetes involve loss of beta-
cell mass and function. In T1D, autoimmune destruction of
beta cells results in an absolute dependence on exogenous
insulin, while the peripheral insulin resistance in T2D can
lead to beta-cell decompensation and failure [1]. Overall
beta-cell mass is regulated by various processes, includ-
ing apoptosis, diﬀerentiation, neogenesis, and proliferation.
Ways to increase beta-cell mass in vivo could provide new
avenues for therapeutic development.
Beta-cell replacement is therapeutic for the treatment
of T1D. The Edmonton protocol for islet transplantation
demonstrated that patients could achieve insulin indepen-
dence one year after the procedure. However, patients re-
quired islets from at least two donors, exceeding organ
supply. In a follow-up study of 36 recipients of islet treated
at nine transplantation centers [2] only one-third of patients
were insulin-independent after two years. These results
demonstrate that increasing beta-cell mass can result in
insulin independence, but that we may need methods in
addition to islet transplantation to achieve this goal.
It remains unclear whether beta-cell proliferation can be
exploited to treat diabetes by inducing beta-cell regeneration.
Beta-cell mass is maintained at optimal levels in the body
through a slow turn-over rate. In humans, it has been shown
that beta-cell mass expands several fold from birth and
through the first three years of childhood, but that after
this initial period, beta-cell replication potential declines
markedly until adulthood [3].
Work in 2004 conclusively showed that new beta cells in
the mouse arise from cell division of existing beta cells and
not from a stem-cell population [4]. As mentioned, study of
pancreatic samples from young human donors showed that
replication is indeed responsible for beta-cell expansion, but
only for a short period after birth [3]. However, an analysis of
donors between 7 and 66 years old found beta cells positive
for the proliferation marker Ki67 in every sample tested [5].
These observations support the hypothesis that beta cells
have a physiological, albeit limited, capacity to proliferate.
A critical barrier to progress in the treatment of diabetes
is the lack of small-molecule drugs to induce beta-cell
regeneration. Small molecule-induced beta-cell proliferation
in humans could be an important way to achieve this goal;
such compounds could be used to restore beta-cell mass in
vivo, or alternatively provide methods for ex vivo expansion
of beta-cell numbers before transplantation. We present here
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an overview of the current trends involving small-molecule
approaches to induce beta-cell regeneration.
2. Physiological Mechanisms of
Beta-Cell Proliferation
2.1. Glucose. Although beta-cell mass remains relatively
constant throughout adulthood, there are a number of phys-
iological stimuli that can promote or inhibit beta-cell pro-
liferation; these naturally occurring conditions enable us
to study them and identify novel targets for perturbation.
First, glucose is a mitogen for beta-cell proliferation, with
long- and short-term glucose infusion promoting beta-cell
proliferation [6–8]. Human islets transplanted into nonobese
diabetic mice also responded to glucose in vivo by pro-
liferating [9]. Although the mechanism of glucose-induced
proliferation has remained unclear, the role of, for example,
the insulin receptor and insulin receptor substrate 2 have
been shown to be important [10]. A recent study showed
the importance of glycolytic flux on the stimulation of cell
division [11]. After ablating the majority of beta cells in
mice and inducing compensatory proliferation, the authors
found that beta cells adjust their proliferation rate according
to the rate of glycolysis. Glucokinase (GCK) phosphorylates
glucose to glucose-6-phosphate in the first step of glycolysis.
It serves as a glucose sensor and can regulate insulin secretion
and beta-cell proliferation. Accordingly, mice deficient in
GCK could not compensate for beta-cell ablation by pro-
liferating, while GCK activator compounds increased this
proliferation. Further evidence of GCK importance in beta-
cell proliferation was provided by the identification of a rare
variant (V91L) in the human glucokinase gene, in which
the aﬃnity of GCK for glucose was more than 8.5 times
higher. These individuals have abnormally large islets, larger
relative beta-cell area, and a high degree of proliferation, as
determined by the number of Ki67-positive beta cells [12].
These studies point to GCK as an important target for small-
molecule modulation.
2.2. Pregnancy. A well-studied phenomena associated with
an increase in beta-cell mass is pregnancy. During pregnancy,
the presence of the fetus creates an increased metabolic
demand on the mother, resulting in increased glucose-
stimulated insulin secretion, increased insulin synthesis, and
a reversible increase in beta-cell replication [13, 14]. The
peak of proliferation coincides with an increase in lactogen
levels, such as prolactin, placental lactogen, and growth hor-
mone [15]. Although early examination of cadaveric human
islets showed an enlargement of islet size in pregnancy due to
hyperplasia (from 72% beta cells per islet to 82% in pregnant
women) [16], later studies showed that human islets respond
to lactogens primarily by increasing insulin secretion [17]
and that ductal neogenesis may in fact be occurring during
pregnancy [18].
Despite the ambiguity of the adaptive response to preg-
nancy in humans, recent work has advanced our knowledge
of this process in rodents. Work in 2007 showed that
the increase in beta-cell proliferation in pregnant mice is
mediated by the protein menin, encoded by the Men1
gene [19]. Expression of menin in beta cells perfectly
anticorrelates with the increase in BrdU incorporation in
beta cells during pregnancy. Menin associates with the
histone methyltransferase mixed-lineage leukemia (MLL),
which in turn regulates expression of cell-cycle inhibitors
p18 and p27. Overexpression of menin in islets causes a
decompensation during pregnancy and loss of menin expres-
sion, and downstream consequences could be recapitulated
in cell culture by the addition of prolactin. Consistent
with these results, study of the transcription factor FoxM1
in islets found that pancreas-wide deletion of this gene
resulted in loss of all proliferation during pregnancy and
subsequent development of gestational diabetes [20]. These
eﬀects were accompanied by an increase in menin and p27
levels, suggesting an important role for FoxM1 and menin
in the adaptation to pregnancy. Finally, another study of
pregnancy in mice revealed that the expansion of beta-cell
mass is at least partially regulated by serotonin signaling
[21]. Tryptophan hydroxylase 1, the rate-limiting step in
serotonin biosynthesis, is one of the most highly upregulated
genes in pregnant islets, and the conclusion of the study
was that serotonin acts as a paracrine signal to stimulate
cell-cycle progression in beta cells. All these studies strongly
suggest that researchers should pay particular attention to
this physiological process when thinking about mechanisms
to induce beta-cell regeneration.
2.3. Obesity. The loss of beta-cell mass has been reported
in obesity and T2D [22, 23], although in some cases there
is a compensatory increase in beta-cell mass [24]. Whether
this adaptation is mediated by beta-cell proliferation is not
well understood. Two lines of evidence point to regulation
of proliferation in mouse obesity. First, the mouse model
of hyperphagic obesity, Ay , was used to assess the levels
of menin and downstream cell-cycle proteins. Relative to
nonobese control littermates, Ay mice have much lower
mRNA and protein levels of menin, p18, and p27 [19].
This loss of menin expression correlates with increased
proliferation, though it was not shown explicitly. Second, an
analysis of genes regulated in nondiabetic obese ob/ob mice
revealed that cell-cycle genes were increased in expression.
In particular, FoxM1 is an important regulator of beta-cell
division and is increased in these obese mice [25]. Further,
overexpression of FoxM1 stimulated [3H]-thymidine incor-
poration in whole mouse and human islets. These studies
suggest that the response of beta cells to obesity may be quite
similar to the response during pregnancy.
2.4. Aging. During aging, many tissues lose regenerative ca-
pacity, and the increase in expression of p16INK4a has been
shown to be a marker of aging [26]. This phenomenon is
also observed in islets [27, 28], and aged mouse islets express
far more p16INK4a than exocrine tissue [29]. Mice with p16
deficiency had eﬀects that depended on age: youngmice were
unaﬀected by the loss of the gene, while older mice lost any
beta-cell proliferative capability. Similarly, p27KIP1 protein
accumulates in terminally diﬀerentiated beta cells during
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embryogenesis [30], limiting their postnatal expansion. In
humans, recent results reveal that these regulatory proteins
are activated or inactivated according to the diﬀerent beta-
cell proliferative status. For example, p16 and p27 proteins
were sporadically expressed in prenatal human beta cells, but
were enriched in adult ones [31]. Thus, the eﬀects of aging
appear to be similar in rodent and human islets.
The mechanism of increased expression of cell-cycle
inhibitors during aging is slowly becoming clearer. Aging
in mice is associated with a decrease in expression of
two repressors of the Ink4a/Arf locus. First, aging reduces
expression of the polycomb group protein Bmi-1, resulting
in increased recruitment of MLL and methylation of the
locus, and increased p16 expression [32]. Accordingly, Bmi-
knockout mice have increased p16 expression and decreased
beta-cell mass. Second, aging decreases beta-cell expression
of the histone methyltransferase enhancer of zeste homolog 2
(Ezh2). Conditional deletion of Ezh2 results in expression of
p16 at a younger age and a decrease in beta-cell proliferation
[33]. These studies show that the various adaptations of
beta cells to the physiological stresses of hyperglycemia,
obesity, pregnancy, and aging may all ultimately converge on
regulation of the cell cycle in beta cells.
3. Cellular Targets for Proliferation
3.1. Cell-Cycle Proteins. From a molecular point of view,
beta-cell proliferation is regulated by finely tuning protein
kinases, kinase activators, or inhibitors [34–36]. Here, we will
review relevant cellular proteins that could be targeted for
high-throughput screening. In terms of positive regulation
of beta-cell proliferation, a central role has been ascribed
to cyclin D1 and D2 [37]. The role of cyclin D3 remains
controversial in rodents [38], but its role seems to be more
important in human pancreas [39]. Genetic manipulation
through overexpression is eﬀective in inducing beta-cell
regeneration. One of the first pieces of evidence of induction
in human beta cells came from overexpression of cdk-4
and cyclin D1 in islets [40]. Further, overexpression of the
cyclin-dependent kinase cdk-6, either with or without cyclin
D1, causes an increase in human beta-cell proliferation in
both intact islets and dissociated islet cells [39, 41]. An
important liability in targeting cell-cycle proteins chemically
is their ubiquitous expression throughout the body. In fact,
inhibition of cell-cycle kinases is an active area of research
for cancer therapy [42]. It may be a daunting task to
identify, for example, activators of key cell-cycle proteins
that are specific only to beta cells. As discussed, many of
the important physiological processes regulating beta-cell
proliferation converge on the cell cycle, so this fundamental
process may be too downstream for eﬀective targeting by
small molecules.
3.2. GSK-3β. Multiple lines of evidence indicate that theWnt
pathway is involved in beta-cell survival and proliferation.
Activation of Wnt signaling in beta-cell lines or primary
mouse islets has been shown to result in enhanced beta-
cell proliferation [43–45], with upregulation of cell-cycle
genes, including cyclins D1 and D2, and cdk-4 [45, 46].
Furthermore, increasing beta-catenin expression in islets
causes an expansion of beta-cell mass in vivo, while upregu-
lating axin expression, a negative regulator of Wnt signaling,
blunts Wnt-stimulated gene expression and reduces beta-cell
expansion [46].
In the absence of Wnt signaling, glycogen synthase
kinase-3β (GSK-3β), adenomatous polyposis coli protein,
axin, and beta-catenin form components of the “destruction
complex,” enabling GSK-3β to phosphorylate beta-catenin,
targeting it for ubiquitination and degradation by the
proteasome. GSK-3β inhibitors induce beta-cell prolifera-
tion; treatment of INS-1 cells with structurally unrelated
GSK-3β inhibitors 1-azakenpaullone, CHIR99021, and 6-
bromoindirubin-3’-oxime (BIO) increased proliferation rate
in a dose-dependent manner, as measured by BrdU incorpo-
ration [47]. 1-Azakenpaullone and CHIR99021 were found
to promote beta-cell replication in isolated rat islets. On
the basis of these observations, novel derivatives of paullone
were synthesized and assayed for their eﬀect on beta-cell
proliferation. Among those tested, 1-aza derivatives resulted
in potent and selective GSK-3β inhibitors (Figure 1(a)).
Within this series, 9-cyano-1-azapaullone (cazpaullone)
showed the most eﬃcacy in inducing beta-cell replication
in both INS-1 cells and primary rat islets [48]. Work
in human islets has revealed that GSK-3β inhibitors also
promote proliferation, though the readout was total islet
[3H]-thymidine incorporation [49]. Rapamycin also reduced
this proliferation, further pointing to activation of mTOR as
a potential mechanism for inducing beta-cell proliferation.
With pursuit of novel GSK-3β inhibitors, an active area of
research [50], the question of the role of GSK-3β in beta
cells will be answerable with ever more selective and potent
compounds.
3.3. Glucokinase. As mentioned above, glucokinase (GCK)
phosphorylates glucose to glucose-6-phosphate in the first
step of glycolysis. It is the predominant hexose kinase in
beta cells and plays an important role as a glucose sensor in
beta cells. When fed a high-fat diet, wild-type mice showed
marked beta-cell hyperplasia, while GCK heterozygous mice
could not suﬃciently increase beta-cell replication [55],
leading to the conclusion that glucokinase plays a critical
role in inducing beta-cell replication. To address this aspect,
GCK+/− mice were fed with high-fat diet in the presence or
absence of a glucokinase activator (GKA) for 20 weeks [56].
No significant diﬀerences in beta-cell proliferation were seen
after chronic treatment, but after an acute 3-day treatment
with GKA, beta-cell proliferation was markedly stimulated.
Potent proliferative eﬀects of the glucokinase agonists
GKA50 (Figure 1(b)) and LY2121260 were also observed in
the INS-1 cell model [51]. Interestingly, GKA50, but not
LY2121260, also prevented apoptosis in INS-1 cells under
chronic high-glucose concentrations, probably by increasing
the levels of glucokinase protein itself. Glucokinase agonists
could play important role in promoting beta-cell prolifer-
ation and preventing apoptosis, and novel compounds are
actively being sought for these purposes [57].
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Figure 1: Chemical structures of small molecules reported to induce beta-cell proliferation. (a) 1-Azakenpaullone, a GSK-3β inhibitor [47].
(b) GKA50, a glucokinase activator [51]. (c) PSN632408, a GPR119 agonist [52]. (d) Bay K 8644, an L-type calcium channel activator [53].
(e) 5-Iodotubercidin, an adenosine kinase inhibitor [54].
3.4. GLP-1. Although much study has focused on glucagon-
like peptide 1 (GLP-1) and its role in diabetes, important
questions remain unanswered. For example, the ability of
exendin-4 to induce beta-cell proliferation in rodents is
well established [58–61], but whether this eﬀect also occurs
in humans has not yet been demonstrated [62]. A recent
report showed an increase in the replication of human beta
cells transplanted into mice treated with exendin-4, but
only when the islets were from young donors [63]. Such
observations raise questions about the diﬀerences, in terms
of the molecular machinery and islet physiology, existing
between murine models and humans. On the other hand,
the fact that GLP-1 appears to activate Wnt in a TCF7L2-
dependent manner [64] is encouraging for a translation
to human biology, as single-nucleotide polymorphisms in
TCF7L2 provide the strongest genetic associations with T2D
[65]. It may be the case that such eﬀects of GLP-1 activation
are only observable when administered to a whole organism,
and not in cell culture alone.
There is a great scientific and commercial interest in
identifying GLP-1 mimetics and inhibitors of dipeptidyl
peptidase 4, which degrades GLP-1 in vivo [66]. These com-
pounds promote activation of the GLP-1 G protein-coupled
receptor to stimulate insulin secretion and inhibit glucagon
secretion, and also have the potential to increase beta-
cell mass (see [67] for an extensive review). Despite some
interesting successes, the development of small-molecule
agonists of the GLP-1 receptor is still quite challenging and
not yet fully developed.
3.5. GPR119. G protein-coupled receptor 119 (GPR119) is
another attractive target for T2D therapy [68]. GPR119
was first identified as an orphan GPCR in various
mammalian species [69]. This receptor is predominantly
expressed in beta cells [70] and GLP-1-secreting intestinal
L-cells [70]. The phospholipids lysophosphatidylcholine and
oleoylethanolamide (OEA) are natural endogenous ligands
for GPR119 [71, 72]; each of them increases intracellular
cAMP levels and results in glucose-dependent insulin secre-
tion. Gao et al. [52, 73] evaluated the eﬀects of OEA and
synthetic agonists (PSN632408 and AR231453) on murine
beta-cell replication (Figure 1(c)) and found that all were
able to increase the number of replicated beta cells compared
to control animals. Similar results have been reported for
other GPR119 agonists: AS1535907 [74] and APD597 [75].
These results provide interesting preliminary evidence that
activating GPR119 may be a feasible strategy for treating
T2D.
4. Chemical Screening and
Beta-Cell Proliferation
In the past few years, attempts have been made to develop
assays for high-throughput screening (HTS) to identify
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small-molecule inducers of pancreatic beta-cell expansion.
One of the first studies reported screening a heterocyclic
library of 850,000 compounds for proliferation of the
reversibly immortalized mouse cell line R7T1 [53]. This
beta-cell line was immortalized using the SV40 T antigen
under the control of the Tet-On system, such that the cells
proliferate in presence of tetracycline but undergo growth
arrest upon its withdrawal [76]. These cells express charac-
teristic beta-cell markers (insulin 1, insulin 2, and Pdx1),
secrete insulin, and restore euglycemia in streptozotocin-
treated mice. Although not a true mimic of in vivo quiescent
beta cells, this system can be considered a reasonable proxy
to identify reentry into the cell cycle of growth-arrested cells
as measured by intracellular ATP levels. To rule out false-
positive tetracycline mimetics, the Tet-Oﬀ immortalized
beta-cell line βTC-Tet, which proliferates only in the absence
of Tet [76], was used as a counter screen.
Several structurally diverse, active compound classes
were identified, including phorbol esters, dihydropyridines
(DHP), and thiophene pyrimidines. In particular, the thio-
phene pyrimidines appeared to stimulate beta-cell prolifera-
tion by activating the Wnt signaling pathway. A piperazinyl
derivative showed a dose-dependent induction of R7T1
proliferation with an IC50 of about 1.1 μM. The same
compound was active in MIN6 and HIT-T15 beta-cell lines
and in primary rat beta cells. Interestingly, this molecule
turned out to be a potent GSK-3β inhibitor.
The dihydropyridine (DHP) class identified in this screen
acts on L-type calcium channels. In beta cells, calcium chan-
nels play a key role in controlling glucose-stimulated insulin
secretion and insulin production [77], and polymorphisms
in some calcium channel-encoding genes are associated with
both T1D and T2D [78–80]. However, it is also possible that
these mutations lead to proliferative defects in beta cells. In
fact, the LTCCa1D subunit knockout displayed a significant
reduction of postnatal beta-cell proliferation [81], suggesting
that calcium channel signaling is necessary for beta-cell
replication. The most potent derivative identified (Bay K
8644; Figure 1(d)) resulted in a significant dose-dependent
increase in proliferation of growth-arrested R7T1, HIT-
T15 and MIN6 beta-cell lines, and primary rat beta cells.
Data showing induction of human beta-cell proliferation,
however, were less conclusive, suggesting that further study is
required to identify inducers that are active in human islets.
Recently, we have developed a human islet cell-culture
system [82] to screen for inducers of beta-cell proliferation
directly in primary human cells. While very challenging,
we have used this system to measure the percentage of
insulin+/Ki67+ cells after compound treatment in 384-
well plates. The major limitation is acquiring an adequate
supply of human islets. A proof-of-concept screen using
primary rat islets has also been reported [54]. Dissociated
islets were seeded in 96-well plates and treated with a
library of ∼850 cell-permeable bioactive compounds. The
primary screen measured the percentage of PDX1+/Ki67+
cells. Two adenosine kinase inhibitors: 5-iodotubercidin (5-
IT; Figure 1(e)) and ABT-702 were screening hits, and both
induced a two- to three-fold increase of the percentage of
the PDX1+/Ki67+ cells compared to DMSO-treated controls.
In vivo studies were carried out using ABT-702 due to its
longer half-life; intraperitoneal injection of 21mg/kg ABT-
702 resulted in a two-fold increase in BrdU incorporation
in PDX1+ cells, but had no eﬀect on either exocrine cells
or hepatocytes. No data were presented in human islets, so
it remains to be seen whether adenosine kinase plays an
important role in human beta-cell proliferation.
Adenosine kinase is highly expressed in the liver and pan-
creas [83] and plays an important role in cellular metabolism
[84]. To understand why adenosine kinase inhibitors induce
beta-cell replication, islet cultures were treated with both
5-IT and various replication-pathway inhibitors. Only the
p38 mitogen-activated protein kinase (MAPK) inhibitor
SB203580 increased 5-IT-dependent beta-cell replication,
while rapamycin and the PI3K inhibitor wortmannin each
suppressed beta-cell replication, suggesting 5-IT promotes
beta-cell replication in an mTOR-dependent manner. The
authors also observed an interesting link with glucose and
GLP-1; the combination of 5-IT with high glucose, GLP-
1, or exendin-4 induced the replication rate four- to five-
fold. These results point to adenosine kinase as yet another
possible target for beta-cell regeneration.
5. Future Directions: Cellular
Targets for Screening
An impression that comes from the many studies performed
on beta-cell proliferation is that there seem to be as many
possible targets as there are studies. Because a potential goal
in diabetes regenerative medicine is to induce proliferation
of beta cells, it is important to find mechanisms that are very
specific for beta cells. Otherwise, the risk for any compound
that is identified is that it globally induces cell division, a
potentially catastrophic consequence. In order to identify
selective small molecules, it is likely that future directions
should involve processes that are relatively specific to beta
cells.
The adaptive response of beta cells to pregnancy provides
several possibilities for cellular targets. First, serotonin is
highly upregulated in beta cells during pregnancy [21]. Thus,
activation of serotonin biosynthesis or signaling may be
a novel and specific way to induce beta-cell proliferation.
Increased knowledge of the mechanisms by which serotonin
increases proliferation will help in this quest. Second, the
protein menin is highly downregulated during pregnancy
[19]. Menin is interesting because of its specificity towards
beta cells, and its ability to act as a switch that can turn on or
oﬀ beta-cell proliferation. Recently, these unique properties
have been assessed in a hyperglycemic diabetic mouse
model, where acute and temporally controlled deletion of
Men1 improves preexisting hyperglycemia in streptozotocin-
treated mice, and reverses glucose intolerance in high-fat
diet-fed mice by increasing proliferation of beta cells [85].
A very recent study reports screening for disruption of the
menin-MLL complex [86], so it will be of great interest to
determine whether these compounds also increase beta-cell
proliferation.
The prospect of targeting menin and/or MLL high-
lights the likely important role epigenetics will play in
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understanding beta-cell proliferation in the future. There is
accumulating evidence that beta cells regulate their growth
and fate by epigenetic mechanisms [32, 87]. Thus far,
modulation of epigenetic status has not been fully exploited
in beta-cell physiology and could represent an array of novel
therapeutic targets. Indeed, some interesting examples of the
potential of this approach are already available, particularly
histone deacetylase inhibitors [88, 89]. A number of other
cellular targets provide attractive models, including mTOR
activation, as discussed above, and Pax4 activation [90].
Most of the studies in beta-cell biology, including the
more recent high-throughput screening examples, rely heav-
ily onmurine animal and cell models. Although these studies
provide the foundation for many advances in beta-cell
research, unfortunately they often do not translate to similar
results when applied to humans. The greatest challenge
facing beta-cell regeneration approaches, particularly prolif-
eration, is the requirement for treatments and mechanisms
to work in both rodents and humans. As we understandmore
about the physiological proliferative behavior of human beta
cells, we can start to identify the molecular switches that
could be potentially used to foster the proliferation of beta
cells in humans.
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